Article | September 8, 2021

Key Insights Into Overcoming mRNA Process Challenges

Source: Cytiva

When the COVID-19 pandemic began its outbreak in 2020, the biopharmaceutical industry began its work on developing a vaccine. The vaccines by Moderna and Pfizer-BioNTech using messenger RNA, or mRNA, emerged.

Due to challenges with distribution specificity and stability within the body, until now, mRNA has had a slow uptake in the industry. Scientific advances and an increase in resources and focus dedicated to mRNA research and development during the COVID-19 response have demonstrated its potential as a disruptive technology for the future of medicine.

However, there are still hurdles when it comes to efficient and effective process development of mRNA vaccines and therapies. Key areas and strategies can help alleviate bottlenecks in the growing market segment for mRNA.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development